All the postgenomic world is a stage: The actors and narrators required for translating pharmacogenomics into public health

Personalized Medicine

Volumn 10, Issue 3, 2013, Pages 213-216

  Dove, Edward S ^a,b   Özdemir, Vural ^a,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b LLM Program ^*  (United States)

^c MCGILL UNIVERSITY   (Canada)

^d Data Enabled Life Sciences Alliance International DELSA Global   (United States)

Author keywords

genomics and development; genomics without borders; global governance of biotechnology innovation and uncertainty; LGBT community; LMIC; public health pharmacogenomic; reflexive technology governance; responsible innovation; science and technology studies; taxonomy of knowledge based innovation

Indexed keywords

BIOETHICS; ECOSYSTEM; GOVERNMENT; LOWEST INCOME GROUP; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SOCIOLOGY; TAXONOMY;

EID: 84876099618     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.10     Document Type: Review

References (21)

1. Tutton R. Personalizing medicine: futures present and past. Soc. Sci. Med. 75(10), 1721-1728 (2012).
2. Özdemir V, Muljono DH, Pang T et al. Asia-Pacific Health 2020 and Genomics without Borders: co-production of knowledge by science and society partnership for global personalized medicine. Curr. Pharmacogenomics Person. Med. 9(1), 1-5 (2011).
3. Vayena E, Gourna E, Streuli J, Hafen E, Prainsack B. Experiences of early users of direct-to-consumer genomics in Switzerland: an exploratory study. Public Health Genomics 15(6), 352-362 (2012).
4. Özdemir V, Fisher E, Dove ES et al. End of the beginning and public health pharmacogenomics: knowledge in 'mode 2' and P5 medicine. Curr. Pharmacogenomics Person. Med. 10(1), 1-6 (2012).
5. Özdemir V, Borda-Rodriguez A, Dove ES et al. Public health pharmacogenomics and the design principles for global public goods-moving genomics to responsible innovation. Curr. Pharmacogenomics Person. Med. 11(1), 1-4 (2013).
6. Stirling A. 'Opening up' and 'closing down': power, participation, and pluralism in the social appraisal of technology. Sci. Technol. Human Values 33(2), 262-294 (2008).
7. Wynne B. Misunderstood misunderstanding: social identities and public uptake of science. Public Underst. Sci. 1(3), 281-304 (1992).
8. Wynne B. Public engagement as a means of restoring public trust in science-hitting the notes, but missing the music? Community Genet. 9(3), 211-220 (2006).
9. Dove ES, Faraj SA, Kolker E, Ozdemir V. Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action. Genome Med. 4(11), 91 (2012).
10. Guston DH, Sarewitz D, Miller C. Scientists not immune to partisanship. Science 323(5914), 582 (2009).
11. Fox RC, Swazey JP. Observing Bioethics. Oxford University Press, Oxford, UK (2008).
12. De Vries R. How can we help? From 'sociology in' to 'sociology of ' bioethics. J. Law Med. Ethics 32(2), 279-292 (2003).
13. Dove ES, Özdemir V. 'Regular science' is inherently political. EMBO Rep. 14(2), 113 (2013).
14. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br. J. Clin. Pharmacol. 71(5), 659-671 (2011).
15. Özdemir V. What to do when the risk environment is rapidly shifting and heterogeneous? Anticipatory governance and real-time assessment of social risks in multiply marginalized populations can prevent IRB mission creep, ethical inflation or underestimation of risks. Am. J. Bioeth. 9(11), 65-68 (2009).
16. Epstein S. Impure Science: AIDS, Activism, and the Politics of Knowledge. University of California Press, CA, USA (1996).
17. Aubert E, Haring K, Hopper D et al. Drawing The Line: A Portrait of Keith Haring. Cohn A, Wolff JS (Eds.). Biografilm Associates, NJ, USA (1989).
18. Özdemir V. OMICS 2.0: a practice turn for 21(st) century science and society. OMICS 17(1), 1-4 (2013).
19. Dove ES, Joly Y, Knoppers BM. Power to the people: a wiki-governance model for biobanks. Genome Biol. 13, 158 (2012).
20. Nuffield Council on Bioethics. Emerging Biotechnologies: Technology, Choice and the Public Good. Nuffield Council on Bioethics, London, UK (2012). www.nuffieldbioethics.org/sites/default/files/Emerging-biotechnologies-full- report- web-0.pdf
21. Vaclav Havel. Address by Czech Republic President Vaclav Havel in acceptance of 'Open Society' Prize by the Central European University, Budapest, Hungary, 24 June 1999. http://old.hrad.cz/president/Havel/speeches/1999/2406- uk.html